Project partners
30 partners are commited to PREDICTOM objectives. We are aligned to cover the value chain.
Altoida Inc.
Altoida Inc. has developed a functional cognitive assessment medical device that uses augmented reality to determine a user’s function in several areas: fine motor coordination, perceptual motor coordination, cognitive processing speed, eye movement, spatial memory, complex attention, visual perception speech and articulation, planning, inhibition, gait, prospective memory, and flexibility.
ALZpath
ALZpath will provide reagents and expertise to support measurement of the leading blood-based biomarker for the detection of Alzheimer’s pathology, phosphorylated tau 217 (pTau217). To advance screening solutions with patient convenience and accessibility in mind, ALZpath will test pTau217 using a novel remote self-collection method and standard venipunctures.
Alzheimer Europe
Alzheimer Europe is an umbrella organisation of 41 national Alzheimer's associations from 36 European countries. Alzheimer Europe will draw on its vast and diverse network to lead the Public Involvement work in PREDICTOM which will also include conducting a literature review and promoting reflection on the social and ethical implications of the project. We will also organise feedback, if required, on materials developed for communication, dissemination and/or engagement activities.
BrainCheck
BrainCheck's digital cognitive assessment and care planning tools enable clinicians to provide crucial cognitive health services at the point of care, reducing the burden on specialist networks and removing barriers to access. Trusted by hundreds of the country’s most prestigious providers and specialists, BrainCheck’s clinically-proven platform has impacted more than 450,000 patients and their families to-date.
CERTH-ITI
Centre for Research and Technology Hellas – Information Technologies Institute (CERTH-ITI) will contribute to executing the measurement protocols, but also in the development of algorithms, using ML techniques over medical and time-series data collected through digital tools and EEG-devices.
Fraunhofer
The AI & Data Science team at Fraunhofer SCAI has long lasting experience and focus on advanced data analytical methods (statistical data mining, AI/ML) for systems and precision medicine with strong emphasis on neurological disorders. The team serves contributes to the development and validation of AI/ML based models to identify patients at risk of a later dementia diagnosis in PREDICTOM.
GE Healthcare
GE HealthCare (GEHC) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and assumes the leading industrial role of PREDICTOM. GE HC’s digital teams in Budapest will develope platform components and AI algorithm. The GE HealthCare Magnetic Resonance (MR) Research team based in Munich will work with the clinical partners to identify MR biomarkers that could be indicative of early stages of Alzheimer's disease.
GN Group
GN is the provider of hearing screening equipment in PREDICTOM. They have extensive knowledge of the implications of hearing loss as a condition, aim to create awareness of the PREDICTOM platform, and capabilities to assist in driving change among the audiological space towards early identification of individuals at risk of cognitive decline through awareness and use of novel technologies such as cognitive screeners as part of the hearing care.
Fundacion para la investigacion del hospital universitario la fe de la communidad Valenciana (HULAFE)
The HULAFE - GIBI2 group has knowledge and expertise in the design of computational solutions for the extraction of reproducible imaging biomarkers using radiomic methods and AI algorithms.
The HULAFE - GINEA group searches for new biomarkers of Alzheimer's disease that could help to obtain an early and minimally invasive diagnosis, as well as the assessment of its prognosis. In addition, the group participates in numerous clinical trials to find a more effective treatment against the disease.
King's College London
King’s will support the activities by providing retrospective data for PREDICTOM imaging biomarkers from the SLAM Image Bank. King’s specializes in digital technologies for people with dementia, including for early detection. They have access to South London and Maudsley NHS Foundation Trust Brain Health CLINIC, a fully remote NHS memory clinic includes video-based interviews, online cognitive and functional assessments. This service will be the base for the clinical assessment for PREDICTOM participants in and around London.
Klinikum der Universität München (KUM)
KUM has extensive experience in the recruitment of patients for clinical trials. KUM is one of the largest academic hospitals in the EU, is the teaching hospital of the highest-ranking German university and has substantial in- and out-patient geriatric psychiatry and neurology services, including a large memory clinic with a highly experienced clinical team for patient recruitment and delivery of the clinical part of the planned work.
Foundation Lygature
The overall programme management is led by LYG, a Dutch non-profit organization with longstanding, hands-on expertise in the management of IMI/IHI projects. Acting as the right hand of the Coordinator (SUS) and the Project Technical Leader (GEHC), LYG will support the Coordinator and the Project Leader in their various duties, will support all beneficiaries in achieving their goals and the overarching project objectives, foster a fruitful and productive environment, and take the role of the “neutral broker” where needed.
Muhdo Health Ltd
MUHDO Health is pioneering epigenetic testing in the workplace and wider community, with the goal of helping people understand their biological age and better predict their future health, bridging the gap between consumer wellness and technology. MUHDO Health will contribute genetic testing kits and reagents as well as the knowhow and labour to analyse the genetic and epigenetic results of people recruited into the PREDICTOM study.
National Institute for Health and Care Excellence (NICE)
NICE will support the development of a consensus statement for screening and diagnosis of early AD by undertaking a review of clinical guidelines in Europe and engaging with patient/carer representatives, clinicians, guideline developers, health and social care practitioners and industry partners. NICE will also support in engagement activities to understand regulatory and HTA evidence requirements for the new platform being developed to maximise the likelihood of its adoption across Europe.
Novo Nordisk A/S
Novo Nordisk is actively involved across work packages to help drive and ensure efficient project execution. Novo Nordisk’s contributions will be based on its broad competences within project management, clinical trials, biomarker research, and within regulatory processes and patient access.
Pharmacoidea Fejleszto es Szolgaltato KFT
PHI will utilise their expertise in therapeutic and diagnostic exploitation of cell surface proteoglycans to analyse blood glycans in patients’ blood samples. Their discovery that the syndecan-3 expression of blood monocytes correlates with the severity of amyloid pathology in the brain will provide the basis for its exploration as a novel biomarker in AD.
Siemens Healthineers
Siemens Healthineers is leading project activities around body fluid biomarkers. With expertise in developing technologies for high throughput fully automated immunoassay platforms with several assays relevant to the diagnostics of Alzheimer’s disease, Siemens Healthineers will support King's College London in testing more advanced cerebral spinal fluid (CSF) and blood-based biomarkers.
Stavanger University Hospital (SUS)
SUS is the Coordinator of PREDICTOM, and will work actively to achieve the projects goals. This will be done in close collaboration with the Project Technical Leader (GEHC), the Project Management Team, the beneficiaries and affiliated partners, with professional support from LYG on program management.
SUS will also participate in the scientific work. For example, as part of WP1 Biomarkers, SUS will conduct research related to the gut microbiome. We will obtain samples from patients that will be sequenced using next-generation sequencing methods. Using bioinformatics and machine learning, we will try to identify features that characterise patients with an increased risk of Alzheimer's disease. In WP 4, SUS is one of the recruiting sites, and has also taken on the role as Sponsor for the clinical study. SUS is Academic Leader for WP5, overseeing the change of current healthcare practice with respect to neuro-degenerative diseases.
Universitätsklinikum Erlangen
UKE is ideally suited for the analysis of extracellular vesicles in plasma, working on extracellular vesicle for more than 20 years and having all relevant assay systems established.The UKE lab is among the very few in the world that investigates the function of plasma vesicles (pEV) in patients with various diseases and through its location in the centre of non-surgical medicine, has access to plasma samples from patients with many different diseases.
The Geneva Memory Center
The Geneva Memory Center is at the interface between the University of Geneva (UNIGE) and the Geneva University Hospital (HUG). With an extensive experience in leading clinical trials, the Center has the capacity to cover all the required activities, starting from recruiting patients in the Swiss French speaking area and proceed with the trials-related assessment with its technological platform (i.e. imaging tools, plasma biomarkers, etc.).
University of Exeter
Exeter will bring its PROTECT digital research platform infrastructure to coordinate data collection and harmonization across the programme, and work towards a digital product that can be embedded in community and healthcare settings in the longer term. Exeter is WP3 Academic Leader, overseeing the platform development and longer term digital infrastructure.
Joanneum Research Forschungsgesellschaft mbH
JR has previous experience with platform development for digital biomarkers, gamified training, and identifying psychophysiological constructs from eye tracking data. JR will apply eye tracking biomarker discovery during gamified interactions with mobile and stationary technologies, apply data governance and data compliance, develop user scenarios and use cases covering the patient journey.
Vrije Universiteit Brussel (VUB)
VUB has extensive experience in research with regard to early and differential diagnosis of Alzheimer’s disease and related disorders and the recruitment of patients with Alzheimer’s disease and related disorders for clinical trials. In PREDICTOM, VUB will share data of different cohorts for biomarker assessment and be involved in the prospective characterisation of memory clinic patients.
Icometrix (ICO)
ICO (Leuven, Belgium; Boston, USA) is the world leader in AI-driven solutions for brain disorders, dedicated to generating data-driven insights and advancing personalized patient care through cutting-edge artificial intelligence. Founded in 2011 as a spin-off from the universities and university hospitals of Leuven and Antwerp, ICO has developed over a decade of deep expertise in imaging AI. In the PREDICTOM project, ICO plays a pivotal role, contributing to the extraction of imaging biomarkers and the development of prognostic models.
